From IV hydration to mental health support, the clinic is devoted to helping the community live better, one patient at a time ...

Clinical stage biotech Tryptamine Therapeutics has achieved a major milestone in the development of its novel IV-infused ...

Special Report: Clinical-stage biotech Tryptamine Therapeutics has achieved a key milestone, successfully completing the ...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home ...

IV drips for hangovers are becoming a flashy trend, but experts warn they may strain vital organs. While they might look ...

As we continually discover new ways to harness emerging AI technology, AI computing clusters are at the front end of a huge ...

The company is deeply embedded in hospital operations, with a large installed base of equipment and a broad consumables ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...

The Hill Helicopters’ fully composite structure HX50 rotorcraft uses oven consolidation and splice joining for a ...

Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) ("Urbanfund" or the "Company"), confirmed today that the Company has filed ...

IIFL Capital expects banks to shake off a muted FY26 and deliver a strong rebound over FY27-28, driven by a modest loan ...